EZH1/EZH2 抑制增强针对多种癌症模型的过继性 T 细胞免疫治疗
EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models.
本研究表明,EZH1/2抑制可将肿瘤重编程为更具免疫原性的状态,并在血液肿瘤和实体瘤的临床前模型中增强ACT的疗效。
66.6分
★★★☆☆
FRONTIER PAPERS
EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models.
本研究表明,EZH1/2抑制可将肿瘤重编程为更具免疫原性的状态,并在血液肿瘤和实体瘤的临床前模型中增强ACT的疗效。
Case Report: A case of heart failure recovery after non-ischemic cardiomyopathy following chimeric antigen receptor T-cell therapy.
本病例展示了 CAR-T 疗法并发症后漫长的心脏恢复过程。
共 2 条
MEMBER ACCOUNT
登录成功会直接打开下一页。